Stock Analysis of Pliant Therapeutics Inc (PLRX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code PLRX
Close 12.13
Change -0.0400 / 0.329 %
Volume 447621
Vol Change 7291.00 / 1.66 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Pliant Therapeutics Inc
PE (TTM)

-1986.54

Very Poor
Price / Book

713.19

Very Poor
Price / Sales

70336.28

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

731751 K

Enterprise Value

679889 K

ROA (TTM)

-32.79

Very Poor
ROE (TTM)

-35.90

Very Poor
Net Margin (TTM)

-3540.65

Very Poor
Revenue

63.40 %

3545.00 K
Net Profit

25.92 %

-155287.00 K
Debt to Equity

0.0240

Excellent
Altman Z Score

10.15

Excellent
Quick Ratio

0

Poor
Cash Ratio

17.33

Excellent


Highs/Lows of Pliant Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week12.73 4.71 % 0.513 % 13.01512.028-May-2430-May-24
Two Week15.27 20.56 % 0.486 % 15.8712.020-May-2430-May-24
One Month11.82 2.62 % 4.80 % 16.5211.7315-May-2401-May-24
Three Month15.87 23.57 % 3.56 % 17.011.2101-Mar-2425-Apr-24
Six Months13.89 12.67 % 15.54 % 19.6211.2108-Jan-2425-Apr-24
One year21.63 43.92 % 26.26 % 24.7411.2114-Jun-2325-Apr-24
Two year5.63 115.45 % 27.72 % 36.6411.2127-Jan-2325-Apr-24


Technical View of Pliant Therapeutics Inc
RSI

35.50

Neutral
MACD

-0.298

Mild Bearish
ADX

21.45

Neutral
Super Trend

14.81

Strong Bearish
Williams %R

-97.12

Mild Bearish
CCI

-139.71

Mild Bullish


EMA 5

12.60

Mild Bearish
EMA 15

13.33

Strong Bearish
EMA 50

13.89

Bearish
EMA 100

14.63

Mild Bearish
SMA 100

15.11

Mild Bearish
SMA 200

15.46

Strong Bearish
SMA 5 / 20

12.51 / 13.82

Strong Bearish
SMA 15 / 50

13.85 / 13.69

Mild Bullish
SMA 50 / 200

13.69 / 15.46

Strong Bearish




Charts of Pliant Therapeutics Inc


Returns of Pliant Therapeutics Inc with Peers
Period / StockPLRXCTKBGHRSEMBC
1 Week-4.71%-5.54%2.85%-5.79%
1 Mth2.62%-6.32%28.56%22.11%
3 Mth-23.57%-26.88%58.67%-13.38%
6mth-12.67%-18.88%125.80%-32.55%
1 Year-43.92%-27.91%25.80%-55.29%
2 Year115.45%-42.02%40.62%-50.08%
5 Years----
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Pliant Therapeutics Inc with Peers
Ratio / StockPLRXCTKBGHRSEMBC
PE-1986.54-70.12-22.868.57
P/B713.191.833.27-0.749
ROA-32.79-2.10-13.865.76
ROE-35.90-2.61-14.310
Debt To Equity0.02400.01830.0016-1.96
Revenue3545.00 K
63.40 % 		183118 K
11.63 % 		0
% 		1120.80 M
0.770 %
Net Income-155287.00 K
25.92 % 		-14122.00 K
668.52 % 		-35587.00 K
398.77 % 		70400.00 K
68.52 %


Technicals of Pliant Therapeutics Inc with Peers
Technical / StockPLRXCTKBGHRSEMBC-
ADX21.4512.0944.2531.10
CMF-0.202-0.198-0.064-0.240
MFI42.2621.0257.1523.74
RSI35.5033.9962.3246.84
MACD Abv SignalFalseFalseTrueFalse
Price Above 50 MAFalseFalseTrueTrue-
Price Above 200 MAFalseFalseTrueFalse-


About : Pliant Therapeutics Inc

Address : 260 Littlefield Avenue, South San Francisco, CA, United States, 94080
Tel : 650 481 6770
URL : https://pliantrx.com
Code : PLRX, ISIN : US7291391057, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 03_Jun_2020
Employee Count : 158

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)